Skip Navigation
Print Page

Staff Detail

Skip sharing on social media links
Share this:

Weinberg, DAVID

Formal Title:

Project Lead for the Human Placenta Project


David Weinberg is acting as project lead for NICHD's Human Placenta Project. This role includes generation of funding opportunities and management of grants related to assessment of human placental development and function across pregnancy. It also includes outreach to diverse scientific communities to raise awareness for this initiative.





6100 EXECUTIVE BLVD Room 4B15, MSC 7510
Bethesda Md 20892-7510
For FedEx use:
Rockville Md 20852

Topics in my portfolio:


David Weinberg received his Ph.D. from the Johns Hopkins University in 1983 for work on the Adenovirus type 2 early region 4.  Following a postdoctoral fellowship, he  joined the pharmaceutical company Merck &Co. in 1989.  Dr. Weinberg spent the next 2 decades in early stage drug discovery focused on a broad array of targets aimed at the treatment of obesity while gaining experience across all aspects of translational research and preclinical drug development.  In 2009, he joined the National Institutes of Health (NIH) as a Health Science Administrator where he managed the review of grant applications across a broad spectrum of scientific topics with particular emphasis in the area of female reproductive research.  In 2014, Dr. Weinberg became the Project Lead for NICHD’s newly launched Human Placenta Project.  The goal of this project is to accelerate the progress towards safe, non-invasive, real-time assessment of placental structure and function across pregnancy.

Featured Items:

The Human Placenta Project:

Publications (PubMed):

Title Authors Publication Date
The role of melanocortins in body weight regulation: opportunities for the treatment of obesity.MacNeil DJ,Howard AD,Guan X,Fong TM,Nargund RP,Bednarek MA,Goulet MT,Weinberg DH,Strack AM,Marsh DJ,Chen HY,Shen CP,Chen AS,Rosenblum CI,MacNeil T,Tota M,MacIntyre ED,Van der Ploeg LHEur J Pharmacol2002 Aug 16
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist.Hong Q,Bakshi RK,Palucki BL,Park MK,Ye Z,He S,Pollard PG,Sebhat IK,Liu J,Guo L,Cashen DE,Martin WJ,Weinberg DH,MacNeil T,Tang R,Tamvakopoulos C,Peng Q,Miller RR,Stearns RA,Chen HY,Chen AS,Strack AM,Fong TM,MacIntyre DE,Wyvratt MJ,Nargund RPBioorg Med Chem Lett2011 Apr 15
Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity.He S,Ye Z,Dobbelaar PH,Bakshi RK,Hong Q,Dellureficio JP,Sebhat IK,Guo L,Liu J,Jian T,Lai Y,Franklin CL,Reibarkh M,Holmes MA,Weinberg DH,MacNeil T,Tang R,Tamvakopoulos C,Peng Q,Miller RR,Stearns RA,Chen HY,Chen AS,Strack AM,Fong TM,Wyvratt MJ Jr,Nargund RPBioorg Med Chem Lett2010 Nov 15
Vision National Institutes of Health Home BOND National Institues of Health Home Home Storz Lab: Section on Environmental Gene Regulation Home Machner Lab: Unit on Microbial Pathogenesis Home Division of Intramural Population Health Research Home Bonifacino Lab: Section on Intracellular Protein Trafficking Home Lilly Lab: Section on Gamete Development Home Lippincott-Schwartz Lab: Section on Organelle Biology